Cargando…

CAR Chase: Where Do Engineered Cells Go in Humans?

Chimeric antigen receptor (CAR) – and T-cell receptor (TCR) – modified T-cells are rapidly emerging as a viable treatment option for cancer patients. While initial clinical trials for these CAR T cells showed response rates of over 90% in some cases, retrospective studies have revealed a wide variab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krebs, Simone, Dacek, Megan M., Carter, Lukas M., Scheinberg, David A., Larson, Steven M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518311/ https://www.ncbi.nlm.nih.gov/pubmed/33042849 http://dx.doi.org/10.3389/fonc.2020.577773

Ejemplares similares

Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications
por: Kurtz, Keifer, et al.
Publicado: (2023)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Promoting Physical Activity in Pediatric Oncology. Where Do We Go from Here?
por: Viña, Carolina Chamorro, et al.
Publicado: (2013)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
por: Markman, Maurie
Publicado: (2016)

Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
por: Zeng, Huihua, et al.
Publicado: (2021)

Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?
por: Dhawan, Annika, et al.
Publicado: (2022)

Cancer treatment data available in European cancer registries: Where are we and where are we going?
por: Giusti, Francesco, et al.
Publicado: (2023)

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
por: Qu, Chunrun, et al.
Publicado: (2022)

Where are we going with sentinel nodes mapping in ovarian cancer?
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2022)

Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Where We Are and Where We Need to Go
por: Liu, Xiaohao, et al.
Publicado: (2020)

Point-of-care screening for atrial fibrillation: Where are we, and where do we go next?
por: Ashburner, Jeffrey M., et al.
Publicado: (2021)

Health Psychology: Where Are We And Where Do We Go From Here?
por: Kaplan, Robert M.
Publicado: (2009)

Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
por: Magnani, Chiara F., et al.
Publicado: (2020)

Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
por: Ottenhoff, Tom H. M., et al.
Publicado: (2012)

Spatial behavior in rehabilitated orangutans in Sumatra: Where do they go?
por: Fechter, Dominik, et al.
Publicado: (2019)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Where Do Phosphosites Come from and Where Do They Go after Gene Duplication?
por: Diss, Guillaume, et al.
Publicado: (2012)

Nanoparticles in the environment: where do we come from, where do we go to?
por: Bundschuh, Mirco, et al.
Publicado: (2018)

Where Do Omics and Markers Go Next?
por: Sharp, Frank R.
Publicado: (2010)

WHERE DO WE GO FROM HERE?
por: Kuruvilla, K.
Publicado: (1994)

Where Do Old Colliders Go to Die?
Publicado: (2009)

Translational Research: Where Do We Go?
por: Kim, Nam Kug, et al.
Publicado: (2012)

Where do we go from here
por: Ranganathan, Kannan
Publicado: (2012)

Where Do Patients Go for Treatment of Urethritis?
por: Hoscan, Mustafa Burak, et al.
Publicado: (2014)

Where Do we Go from Here …
por: Dickson-Deane, Camille
Publicado: (2020)

Where Do They Come from and Where Do They Go: Candidates for Regulating Extracellular Vesicle Formation in Fungi
por: Oliveira, Débora L., et al.
Publicado: (2013)

Editorial: Inflammation and blood diseases, a dog chasing its tail
por: Cumbo, Cosimo, et al.
Publicado: (2023)

Neuropsychiatry: Where Are We And Where Do We Go From Here?
por: Sachdev, Perminder S., et al.
Publicado: (2013)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
por: Laine, Christopher G., et al.
Publicado: (2020)

Chasing Zero Harm in Radiation Oncology: Using Pre-treatment Peer Review
por: Vijayakumar, Srinivasan, et al.
Publicado: (2019)

EEG Recordings as Biomarkers of Pain Perception: Where Do We Stand and Where to Go?
por: Zis, Panagiotis, et al.
Publicado: (2022)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

Psychopharmacology Today: Where are We and Where Do We Go From Here?
por: Schwartz, Thomas L.
Publicado: (2010)

Bacterial EPIYA effectors – Where do they come from? What are they? Where are they going?
por: Hayashi, Takeru, et al.
Publicado: (2013)

Precision medicine in COPD: where are we and where do we need to go?
por: Sidhaye, Venkataramana K., et al.
Publicado: (2018)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Dermatology education in skin of colour: where we are and where do we go?
por: Onasanya, Joshua, et al.
Publicado: (2021)

The future of high-grade glioma: Where we are and where are we going
por: Rhun, Emilie Le, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mbusltma89as48e4pmihe9e8v5